Advances in research to restore vision

Mammalian eyes have a limited ability to regenerate once neurons degenerate. This results in visual impairment that impacts the quality of life among adult populations as well as in young children leading to lifelong consequences. Various therapies are in development to restore vision, and these include gene therapy, stem cell therapy, in-vivo transdifferentiation, and transplantation of a patient’s whole eye obtained from interspecies blastocyst complementation. This review discusses advances in the research as well as hurdles that need to be resolved to have a successful restoration of vision

Ciliary neurotrophic factor-mediated neuroprotection involves enhanced glycolysis and anabolism in degenerating mouse retinas

Ciliary neurotrophic factor (CNTF) acts as a potent neuroprotective cytokine in multiple models of retinal degeneration. To understand mechanisms underlying its broad neuroprotective effects, we have investigated the influence of CNTF on metabolism in a mouse model of photoreceptor degeneration. CNTF treatment improves the morphology of photoreceptor mitochondria, but also leads to reduced oxygen consumption and suppressed respiratory chain activities. Molecular analyses show elevated glycolytic pathway gene transcripts and active enzymes. Metabolomics analyses detect significantly higher levels of ATP and the energy currency phosphocreatine, elevated glycolytic pathway metabolites, increased TCA cycle metabolites, lipid biosynthetic pathway intermediates, nucleotides, and amino acids. Moreover, CNTF treatment restores the key antioxidant glutathione to the wild type level. Therefore, CNTF significantly impacts the metabolic status of degenerating retinas by promoting aerobic glycolysis and augmenting anabolic activities. These findings reveal cellular mechanisms underlying enhanced neuronal viability and suggest potential therapies for treating retinal degeneration

A missense variant in SHARPIN mediates Alzheimer's disease-specific brain damages

Established genetic risk factors for Alzheimer's disease (AD) account for only a portion of AD heritability. The aim of this study was to identify novel associations between genetic variants and AD-specific brain atrophy. We conducted genome-wide association studies for brain magnetic resonance imaging measures of hippocampal volume and entorhinal cortical thickness in 2643 Koreans meeting the clinical criteria for AD (n = 209), mild cognitive impairment (n = 1449) or normal cognition (n = 985). A missense variant, rs77359862 (R274W), in the SHANK-associated RH Domain Interactor (SHARPIN) gene was associated with entorhinal cortical thickness (p = 5.0 x 10(-9)) and hippocampal volume (p = 5.1 x 10(-12)). It revealed an increased risk of developing AD in the mediation analyses. This variant was also associated with amyloid-beta accumulation (p = 0.03) and measures of memory (p = 1.0 x 10(-4)) and executive function (p = 0.04). We also found significant association of other SHARPIN variants with hippocampal volume in the Alzheimer's Disease Neuroimaging Initiative (rs3417062, p = 4.1 x 10(-6)) and AddNeuroMed (rs138412600, p = 5.9 x 10(-5)) cohorts. Further, molecular dynamics simulations and co-immunoprecipitation indicated that the variant significantly reduced the binding of linear ubiquitination assembly complex proteins, SHPARIN and HOIL-1 Interacting Protein (HOIP), altering the downstream NF-kappa B signaling pathway. These findings suggest that SHARPIN plays an important role in the pathogenesis of AD.N